Compare Stocks

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ITRM Iterum Therapeutics	$1.43	$1.51	$0.62 ▼ $2.50	$23.50M	2.36	523,775 shs	59,817 shs
MLND Millendo Therapeutics	$3.17 -3.1%	$4.00	$0.92 ▼ $16.95	$60.37M	0.48	1.52 million shs	316,619 shs
NEOS Neos Therapeutics	$1.15	$1.06	$0.45 ▼ $1.68	$57.22M	1.5	7.44 million shs	15.01 million shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ITRM Iterum Therapeutics	-0.69%	-11.73%	-13.33%	-24.74%	+20.17%
MLND Millendo Therapeutics	-2.39%	-15.06%	-15.50%	-17.01%	+47.96%
NEOS Neos Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

The A.I. story nobody is telling you (Read ASAP) (Ad)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ITRM Iterum Therapeutics	0.8502 of 5 stars	3.5	2.0	0.0	0.0	0.6	0.0	0.6
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NEOS Neos Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ITRM Iterum Therapeutics	3.00	Buy	$6.00	319.58% Upside
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A
NEOS Neos Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest NEOS, ITRM, and MLND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/1/2024	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
3/6/2024	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
2/7/2024	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$6.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.48) per share	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
NEOS Neos Therapeutics	$64.65M	0.89	N/A	N/A	($0.12) per share	-9.58

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ITRM Iterum Therapeutics	-$38.37M	-$2.97	N/A	N/A	N/A	N/A	-664.00%	-87.64%	5/10/2024 (Estimated)
MLND Millendo Therapeutics	-$36.41M	N/A	0.00	∞	N/A	N/A	-91.03%	-72.44%	N/A
NEOS Neos Therapeutics	-$16.90M	-$0.34	N/A	N/A	N/A	-38.35%	N/A	-28.46%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	N/A
NEOS Neos Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ITRM Iterum Therapeutics	3.63	1.89	1.89
MLND Millendo Therapeutics	N/A	6.39	6.39
NEOS Neos Therapeutics	N/A	0.66	0.53

Ownership

Institutional Ownership

Company	Institutional Ownership
ITRM Iterum Therapeutics	9.21%
MLND Millendo Therapeutics	N/A
NEOS Neos Therapeutics	33.13%

Insider Ownership

Company	Insider Ownership
ITRM Iterum Therapeutics	5.40%
MLND Millendo Therapeutics	N/A
NEOS Neos Therapeutics	3.80%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ITRM Iterum Therapeutics	14	16.43 million	15.54 million	Not Optionable
MLND Millendo Therapeutics	12	19.04 million	N/A	Not Optionable
NEOS Neos Therapeutics	213	49.76 million	N/A	Optionable

NEOS, ITRM, and MLND Headlines

Source	Headline
	Avenue Bank wins full APRA licence, bank guarantees in sight afr.com - March 3 at 7:20 PM
	Tema ETF Trends: The Next Generation of Cardiovascular Drugs asiaone.com - February 20 at 3:28 PM
	Presidio Partners 2007 GP, L.P.'s Net Worth benzinga.com - February 9 at 6:00 PM
	USAntibiotics Expands Leadership Team with Appointment of Steven Lutz to Vice President of Strategic Accounts finance.yahoo.com - December 14 at 12:59 PM
	China Eastern orders 25 GEnx turbofans for 787s and Xiamen picks Leap-1A for A320neos flightglobal.com - November 6 at 7:48 PM
	Avenue Bank ready to tap into overlooked market itnews.com.au - November 5 at 6:17 PM
	Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors finanznachrichten.de - September 11 at 7:19 AM
	Aytu BioPharma, Inc.: Aytu BioPharma Announces Submission of Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement finanznachrichten.de - July 10 at 12:32 PM
	Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement finance.yahoo.com - July 10 at 12:32 PM
	ADHD Therapeutics Market Size Worth USD 19740 Million by 2030 at 7.80% CAGR – Report by Market Research Future (MRFR) finance.yahoo.com - May 29 at 12:22 PM
	Overview of Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Dynamics and Trends for 2023-2030 marketwatch.com - May 12 at 12:23 AM
	Global ADHD Medication Market Analysis and Business Growth Outlook [2023-2030] marketwatch.com - April 28 at 8:27 PM
	Attention Deficit Hyperactivity Disorder (ADHD) Market by Product Type and Consumers-2030 marketwatch.com - April 11 at 1:14 PM
	Attention Deficit Hyperactivity Disorder (ADHD) Market 2023 Size and Forecast to 2031 marketwatch.com - April 4 at 3:57 PM
	Attention Deficit Hyperactivity Disorder Market to Register a Steady CAGR of 4.40% Between 2023 – 2031 \| Growth Plus Reports benzinga.com - April 3 at 8:23 AM
	ADHD Medication Market 2023 Size and Growth Forecast to 2028 marketwatch.com - March 30 at 6:56 AM
	2023 Attention Deficit Hyperactivity Disorder (ADHD) Market: Top Players Best Practices and Sales Forecast 2030 marketwatch.com - March 27 at 8:39 AM
	ADHD Medication Market Outlook and Forecast till 2030 marketwatch.com - March 24 at 1:02 PM
	Attention Deficit Hyperactivity Disorder (ADHD) Market Insights and Forecast to 2028 marketwatch.com - March 21 at 6:52 AM
	Syneos Health inks deal with Microsoft to use AI technology endpts.com - March 20 at 5:46 PM
	This report on ADHD Medication market presents a timeline of technical development and discusses how it affects the market. marketwatch.com - March 16 at 3:43 PM
	ADHD Medication Market Analysis, Share by 2028 marketwatch.com - March 14 at 9:36 AM
	Global Methylphenidate Drug Market Research Covers, Future Trends and Opportunities, Past, Present Data, and Deep Analysis 2030 By VMReports marketwatch.com - February 27 at 5:06 PM
	Children Attention Deficit and Hyperactivity Disorder Market 2023: Strategies for Expanding into New Markets across Regions 2029 marketwatch.com - February 19 at 2:55 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Iterum Therapeutics

NASDAQ:ITRM

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Millendo Therapeutics

NASDAQ:MLND

As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.

Neos Therapeutics

NASDAQ:NEOS

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial